CELLMID'S shares have soared after the Australian biotech company announced it will acquire Japanese business Advangen.
Advangen owns the hair growth technology behind Cellmid's over the counter hair growth lotion Evolis and the two companies have worked closely together in recent years.
At 1511 AEST shares in Cellmid jumped 0.8 cents, or 32 per cent, to 3.3 cents.
Cellmid said in a statement that the deal gives it full ownership of the hair growth technology as well access to the Japanese market through Advangen's products.
"The acquisition has important strategic aspects for Cellmid," the company said.
"The company will gain immediate access to the established Japanese hair growth market."
The acquisition also means that Cellmid will no longer have to pay royalties for the use of the hair growth technology and is expected to deliver the company savings on the costs of the active ingredients.
"Our objective is to establish Cellmid as a global leader in scientifically and clinically validated hair growth technology," chief executive Maria Halasz said.
"We plan on generating substantial revenues in the next three to five years."
The acquisition is expected to take up to two weeks.
Cellmid also develops therapies and diagnostic tests for inflammatory diseases, heart attack and cancer.
Anda sedang membaca artikel tentang
Cellmid to acquire Japan biotech Advangen
Dengan url
http://suarabisikan.blogspot.com/2013/05/cellmid-to-acquire-japan-biotech.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Cellmid to acquire Japan biotech Advangen
namun jangan lupa untuk meletakkan link
Cellmid to acquire Japan biotech Advangen
sebagai sumbernya
0 komentar:
Posting Komentar